MDS Reports Second Quarter 2009 Financial Results



    TORONTO, June 11 /CNW/ - MDS Inc. (TSX: MDS; NYSE:   MDZ), a leading
provider of products and services to the global life sciences markets, today
reported financial results for the three-month period ended April 30, 2009. On
a GAAP basis, MDS reported total revenue of $282 million, a net loss of $17
million and a loss per share of $0.15 for the second quarter of 2009. These
results include a non-cash asset write-down of $16 million. Net revenue was
$257 million and adjusted EBITDA was $31 million, compared with $326 million
and $34 million in the prior year, respectively. For the quarter, the Company
announced adjusted earnings per share of $0.03, compared with $0.08 in the
corresponding period a year ago.

    
    Quarterly Highlights

    -   Net revenue of $257 million, down 21% from $326 million in the prior
        year. Excluding the impact of foreign exchange, acquisitions and
        divestitures, net revenue decreased 10%.
    -   Adjusted EBITDA of $31 million with 12% margin, versus $34 million
        with 10% margin in the prior year, as $15 million in restructuring
        and productivity savings largely offset market declines.
    -   Adjusted earnings per share of $0.03, compared with $0.08 in the
        prior year, primarily driven by lower adjusted EBITDA and higher
        interest expense.
    -   Period-end cash position increased $94 million to $243 million.
    -   New product introductions to provide customers with advanced
        technology and improved performance, including the AB SCIEX TOF/TOF
        (TM) 5800 system, a new administration system for TheraSphere(R), a
        suite of iMethods tests, and MetaXpress(TM) analysis software.
    

    "With a vigilant focus on productivity, we offset declines in a soft
market, and delivered solid margins and strong cash flow within the quarter,"
said Stephen P. DeFalco, President and Chief Executive Officer, MDS Inc. "We
continue to maintain a balance of disciplined cost control and strategic
investments to make the Company more competitive during this challenging
economic period."

    
    Operating Segment Results

    MDS Pharma Services

                                                                    % Change
    (millions of U.S. dollars)             Q2 2009      Q2 2008     Reported
    -------------------------------------------------------------------------
    Net Revenue
    Early Stage                            $    56      $    68         (18%)
    Late Stage                                  49           60         (18%)
    -------------------------------------------------------------------------
                                               105          128         (18%)
    Reimbursement revenue                       25           24
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Total revenue                          $   130      $   152
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Adjusted EBITDA                        $     3      $    (1)         n.m.
                                                3%          (1%)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    n.m. - not meaningful
    

    For the second quarter, MDS Pharma Services reported adjusted EBITDA of
$3 million, compared with a loss of $1 million last year. This $4 million
year-over-year increase was largely due to productivity gains and
restructuring savings, partially offset by lower volumes. Net revenue
decreased 18% over the prior-year period with foreign exchange negatively
impacting revenue by $9 million. In the second quarter, Late Stage declines
were primarily due to lower demand in Central Labs. In Early Stage, declines
were largely driven by lower revenues in bioanalytical services.
    MDS Pharma Services recorded new business wins totaling $114 million, a
sequential increase of 10%, compared with new business wins in the first
quarter, but down 31% compared with $165 million of new business wins last
year. The sequential improvement was primarily driven by solid orders in Phase
II-IV and Early Stage bioanalytical services. The year-over-year decline was
largely due to the impact of foreign exchange and slower market demand as
customers reprioritize their research and development (R&D) projects.
Period-end backlog was $442 million, down 11% from $496 million in the prior
year. This decrease is primarily related to changes in foreign exchange and
declines in Late Stage, partially offset by a 10% increase in Early Stage
backlog.
    As part of the Company's quarterly balance sheet assessment, a non-cash
write-down of $16 million was recorded in the second quarter to reflect the
current fair value of MDS Pharma Services Central Labs fixed assets.
    Subsequent to the quarter, as part of its ongoing strategic review
process, MDS announced that it will strategically focus MDS Pharma Services on
the delivery of Early Stage (Discovery through Phase IIa) services where the
Company has a top-three market position. As a result, MDS intends to sell its
Late Stage (Phase II-IV and Central Labs) operations. On June 1, 2009, the
Company announced an agreement to sell its Phase II-IV operations to INC
Research, Inc. for approximately $50 million, including certain transition
services and customary post-closing contingencies and adjustments. This sale
is expected to close during MDS's fiscal third quarter of 2009 (the three
months ending July 31, 2009). A suitable buyer is being sought for Central
Labs.
    To further improve operating performance in a challenging economic
environment, to sharpen the Company's focus on Early Stage, and to reduce
overhead associated with the exit from Late Stage, MDS Pharma Services has
initiated restructuring actions in the third quarter of 2009. MDS estimates
the cost of this restructuring to be approximately $4 million, impacting some
180 people and generating roughly $9 million in annual savings. As the Company
plans to sell these operations, Late Stage will no longer be classified as
part of continuing operations for financial reporting beginning in the third
quarter of 2009.
    To further build core competencies in Early Stage, MDS Pharma Services
initiated a project in the second quarter to renovate and expand its
preclinical operations in Taiwan. The expanded facility will double the
previous capacity to better serve emerging demand for services in the
Asia-Pacific region.

    
    MDS Nordion

                                                                    % Change
    (millions of U.S. dollars)             Q2 2009      Q2 2008     Reported
    -------------------------------------------------------------------------
    Net revenue                            $    65      $    80         (19%)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Adjusted EBITDA                        $    23      $    24          (4%)
                                               35%          30%
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    

    MDS Nordion reported adjusted EBITDA of $23 million in the second
quarter, down 4% compared with last year, and included an embedded derivative
gain of $3 million, versus a gain of $2 million last year. Excluding
divestitures and foreign exchange, adjusted EBITDA increased 12% compared with
last year. Revenue for the second quarter was $65 million, compared with $80
million last year. Excluding the $10 million negative impact of foreign
exchange and $10 million related to the divestiture of certain product lines,
revenue increased by $4 million, or 6% year-over-year. Excluding the
divestitures and foreign exchange, year-over-year improvement in revenue and
adjusted EBITDA was primarily driven by strength in medical isotopes.
    During the quarter, MDS Nordion launched an improved TheraSphere(R)
administration system for physicians. TheraSphere(R) is a targeted internal
radiation therapy for patients with inoperable, primary liver cancer. The new
administration system allows for safer, faster, and more efficient
administration of TheraSphere(R), providing better treatment delivery for
patients.
    Subsequent to the quarter, MDS Nordion commenced the manufacture of
Cardiogen-82(R) (Rubidium-82 generators) for Bracco Diagnostics Inc. (Part of
Bracco Group). CardioGen-82 is the only generator-based, cardiac Positron
Emission Tomography (PET) perfusion imaging agent approved by the United
States Food and Drug Administration (FDA). PET is a highly sensitive
medical-imaging technique that produces a three-dimensional image of the
functioning heart, allowing the cardiologist to identify regions of the heart
muscle receiving poor blood flow.
    After the end of the quarter, in May 2009, Atomic Energy of Canada
Limited (AECL) announced that its National Research Universal (NRU) reactor
would be out of service for at least three months. Based on historical EBITDA
trends related to NRU-supplied isotopes, MDS expects the financial impact of
this shutdown to reduce MDS Nordion's adjusted EBITDA by approximately $4
million for every month the NRU is out of service. MDS is assessing plans to
reduce costs over the extended shutdown period. MDS Nordion continues to
deliver positive EBITDA from sterilization technologies and
radiopharmaceutical product and service lines.
    MDS continues to work to secure a long-term reliable supply of medical
isotopes. In 1996, MDS Nordion contracted with AECL to complete and commission
the MAPLE reactors, which were intended to replace the NRU. In May 2008, this
project was unilaterally discontinued by AECL and the Government of Canada.
MDS invested over $350 million in the MAPLE project, and believes that the
completion of the MAPLE reactors is the best solution to provide global
medical isotope supply. More recently, MDS Nordion urged the AECL and Canadian
Government to consult with international experts and obtain their assistance
to activating the MAPLE project to address the current medical-isotope supply
shortage. In addition, MDS Nordion is examining longer-term supply
alternatives and announced in the second quarter its collaboration with
TRIUMF, Canada's national laboratory for particle and nuclear physics, to
study the feasibility of producing a viable and reliable supply of photo
fission-based Molybdenum-99.

    
    MDS Analytical Technologies

                                                                    % Change
    (millions of U.S. dollars)             Q2 2009      Q2 2008     Reported
    -------------------------------------------------------------------------
    Net revenue                            $    87      $   118         (26%)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Adjusted EBITDA                        $    13      $    17         (24%)
                                               15%          14%
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    

    In the second quarter, MDS Analytical Technologies reported $13 million
in adjusted EBITDA, compared with $17 million in the corresponding quarter
last year. Excluding $5 million of unfavorable impact from foreign exchange,
primarily as a result of hedge positions established in 2008, adjusted EBITDA
increased $1 million or 4%, driven by restructuring and productivity savings,
which were largely offset by pricing and lower volumes. For the quarter, MDS
Analytical Technologies reported $87 million in revenue, down 26% from $118
million in the prior year. The effect of foreign exchange reduced reported
revenue by $11 million, or 9% year-over-year. Including the impact of foreign
exchange, total end-user revenue decreased 13%, with an 11% decline in mass
spectrometry end-user revenue. Soft end-user demand in pharmaceutical markets
for instruments was the primary driver for the year-over-year decline in
volumes across all product lines. The Company continues to see growth in
applied markets, services and new products - particularly the recently
launched 5500 series of mass spectrometers, which are being well received by
customers.
    In the second quarter, MDS Analytical Technologies continued to introduce
innovative technologies and products. The Company and its joint venture
partner, Applied Biosystems (a division of Life Technologies Corporation)
launched the AB SCIEX TOF/TOF(TM) 5800 system - the fastest, most sensitive
MALDI-based mass spectrometer ever built. This system is already commercially
available and will help researchers advance the discovery of biomarkers. MDS
Analytical Technologies and Applied Biosystems also introduced a new suite of
iMethod tests that simplify the use of mass spectrometry for food and water
quality testing, forensic toxicology and clinical research, and
MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 image acquisition and analysis
software, which are designed to accelerate the throughput of high content
screening and expand toxicity applications.

    
    Corporate and Other

                                                                    % Change
    (millions of U.S. dollars)             Q2 2009      Q2 2008     Reported
    -------------------------------------------------------------------------
    Selling, general and administration    $    (7)     $    (7)           -
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Adjusted EBITDA                        $    (8)     $    (6)        (33%)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    

    Corporate selling, general and administration expenses were $7 million in
the second quarter of 2009, level compared with the second quarter of 2008.
These expenses included $3 million in corporate development costs primarily
associated with the sale of MDS Pharma Services' Phase II-IV operations, which
were offset by a $2 million recovery in stock-based compensation expense.
    Relative to cash performance, as of the end of the second quarter, MDS
reported $243 million in cash and cash equivalents, which is approximately
equivalent to the Company's debt position of $276 million minus a government
loan of $39 million, which is entirely offset by a corresponding financial
instrument.

    New Disclosure and Delivery Method for Reporting Financial Results

    In the fourth quarter of 2008, MDS adopted a new approach to releasing
quarterly financial results. The Company no longer uses the newswires to issue
its quarterly Management Discussion and Analysis (MD&A), and financial
statements and notes. For the Company's first, second and third quarters, the
respective MD&A, and financial statements and notes, which are assessable
through this link: http://www.mdsinc.com/investors/financial_results.asp, will
be posted, concurrently with the press release announcing quarterly results,
to the Company's Website at mdsinc.com, and filed with Canadian and U.S.
securities regulators. For fourth quarter results, a press release will be
issued with expanded disclosure. However, fourth quarter results will no
longer be accompanied by an MD&A, and financial statements and notes. A
comprehensive MD&A, with financial statements and notes, will be provided on a
year-end basis with the Company's Annual Report, Annual Information Form and
Proxy Circular filings - all of which will also be posted to mdsinc.com.

    Conference Call

    MDS will hold a conference call today at 9:30 a.m. EDT to discuss second
quarter 2009 results.
    The call will be Webcast live at www.mdsinc.com and will also be
available in archived format at
http://www.mdsinc.com/investors/webcasts_presentations.asp after the call.

    About MDS

    MDS Inc. (TSX: MDS; NYSE:   MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS has more
than 5,000 highly skilled people in 29 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

    Caution Concerning Forward-Looking Statements

    This document contains forward-looking statements. Some forward-looking
statements may be identified by words like "expects", "anticipates", "plans",
"intends", "indicates" or similar expressions. The statements are not a
guarantee of future performance and are inherently subject to risks and
uncertainties. MDS's actual results could differ materially from those
expressed in the forward-looking statements due to these risks and a number of
other factors, including, but not limited to, successful implementation of
structural changes, including restructuring plans and acquisitions, technical
or manufacturing or distribution issues, the competitive environment for MDS's
products and services, the degree of market penetration of its products and
services, the ability to secure a reliable supply of raw materials, the impact
of our clients' exercising rights to delay or cancel certain contracts, the
strength of the global economy, the stability of global equity markets, the
availability and cost of financing, the impact of the movement of the U.S.
dollar relative to other currencies, particularly the Canadian dollar and the
euro, uncertainties associated with critical accounting assumptions and
estimates, and other factors set forth in reports and other documents filed by
MDS with Canadian and U.S. securities regulatory authorities from time to
time, including MDS's quarterly and annual MD&A, Annual Information Form, and
Annual Report on Form 40-F for the fiscal year ended October 31, 2008, filed
with the U.S. Securities & Exchange Commission.
    Also note that all financial data is now shown on a U.S. GAAP basis. MDS
converted to U.S. GAAP reporting with the filing of the Company's 2007 Annual
Report and financial statements on January 29, 2008.

    Use of Non-GAAP Financial Measures

    Non-GAAP measures, including terms such as net revenue, adjusted EBITDA,
adjusted EPS, new orders and backlog, are used to explain the operating
performance of the Company. These terms are not defined by GAAP and MDS's use
may vary from that of other companies. MDS uses certain non-GAAP measures so
that investors and analysts have a better understanding of the significant
events and transactions that have had an impact on results, or may have an
impact on MDS's financial outlook. MDS provides a description of these
non-GAAP measures and a reconciliation of these non-GAAP measures for actual
results to GAAP financial results in its MD&A and Annual Report.

    
    MDS Inc.
    CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
                                                           As of       As of
    (UNAUDITED)                                         April 30  October 31
    -------------------------------------------------------------------------
    (millions of U.S. dollars,
     except share amounts)                                  2009        2008
    -------------------------------------------------------------------------
    ASSETS
    Current assets
    Cash and cash equivalents                           $    243    $    117
    Accounts receivable, net                                 223         264
    Notes receivable                                          14          75
    Unbilled revenue                                          86          86
    Inventories, net                                          88          85
    Income taxes recoverable                                  64          61
    Current portion of deferred tax assets                    18          20
    Prepaid expenses and other                                33          16
    Assets held for sale                                       6           6
    -------------------------------------------------------------------------
    Total current assets                                     775         730

    Property, plant and equipment, net                       278         301
    Deferred tax assets                                       82          95
    Long-term investments                                     25          30
    Other long-term assets                                    98         108
    Intangible assets, net                                   136         155
    Goodwill                                                 455         452
    -------------------------------------------------------------------------
    Total assets                                        $  1,849    $  1,871
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES AND SHAREHOLDERS' EQUITY
    Current liabilities
    Accounts payable and accrued liabilities            $    246    $    266
    Current portion of deferred revenue                       93          79
    Income taxes payable                                       9           1
    Current portion of long-term debt                         36          19
    Current portion of deferred tax liabilities                9           4
    -------------------------------------------------------------------------
    Total current liabilities                                393         369

    Long-term debt                                           240         263
    Deferred revenue                                          11          10
    Other long-term obligations                               33          31
    Deferred tax liabilities                                  81         108
    -------------------------------------------------------------------------
    Total liabilities                                        758         781
    -------------------------------------------------------------------------

    Shareholders' equity
    Common shares at par - Authorized shares:
     unlimited; Issued and outstanding shares:
     120,137,229 and 120,137,229 as of April 30,
     2009 and October 31, 2008, respectively                 489         489
    Additional paid-in capital                                76          75
    Retained earnings                                        286         301
    Accumulated other comprehensive income                   240         225
    -------------------------------------------------------------------------
    Total shareholders' equity                             1,091       1,090
    -------------------------------------------------------------------------
    Total liabilities and shareholders' equity          $  1,849    $  1,871
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    MDS Inc.
    CONSOLIDATED STATEMENTS OF OPERATIONS

                                        Three months              Six months
    (UNAUDITED)                       ended April 30          ended April 30
    -------------------------------------------------------------------------
    (millions of U.S. dollars,                  2008                    2008
     except per share amounts)      2009    Restated        2009    Restated
    -------------------------------------------------------------------------
    Revenues
      Products                  $    135    $    169    $    269    $    320
      Services                       122         157         245         302
      Reimbursement revenues          25          24          43          50
    -------------------------------------------------------------------------
    Total revenues                   282         350         557         672
    -------------------------------------------------------------------------
    Costs and expenses
      Direct cost of products         82         106         164         201
      Direct cost of services         77         101         154         193
      Reimbursed expenses             25          24          43          50
      Selling, general and
       administration                 62          75         122         139
      Research and development        14          22          28          42
      Depreciation and
       amortization                   23          23          45          50
      Restructuring charges, net       -           1           4           1
      Change in fair value of
       embedded derivatives           (3)         (3)          -           1
      Other expenses
       (income), net                  18          (7)         16          (7)
    -------------------------------------------------------------------------
    Total costs and expenses         298         342         576         670
    -------------------------------------------------------------------------

    Operating (loss) income          (16)          8         (19)          2

    Interest expense                  (5)         (3)        (10)         (6)
    Interest income                    3           4           6          10
    Change in fair value
     of interest rate swaps            -           -           -           2
    Equity earnings                    9          10          15          24
    -------------------------------------------------------------------------
    (Loss) income before
     income taxes                     (9)         19          (8)         32
    -------------------------------------------------------------------------

    Income tax (expense) recovery
      - current                       (2)         (3)        (12)        (25)
      - deferred                      (6)         (3)          5          25
    -------------------------------------------------------------------------
                                      (8)         (6)         (7)          -
    -------------------------------------------------------------------------
    Net (loss) income           $    (17)   $     13    $    (15)   $     32
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Basic and diluted (loss)
     earnings per share         $  (0.15)   $   0.11    $  (0.13)   $   0.27
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    MDS Inc.
    CONSOLIDATED STATEMENTS OF CASH FLOWS

                                        Three months              Six months
    (UNAUDITED)                       ended April 30          ended April 30
    -------------------------------------------------------------------------
                                                2008                    2008
    (millions of U.S. dollars)      2009    Restated        2009    Restated
    -------------------------------------------------------------------------
    Operating activities
    Net (loss) income           $    (17)   $     13    $    (15)   $     32
    Adjustments to reconcile
     net (loss) income to cash
     provided by (used in)
     operating activities:
      Items not affecting
       current cash flows             43          (3)         52          22
      Changes in non-cash
       operating assets
       and liabilities                71           4          98        (134)
    -------------------------------------------------------------------------
    Cash provided by (used in)
     operating activities             97          14         135         (80)
    -------------------------------------------------------------------------
    Investing activities
    Purchase of property,
     plant and equipment              (7)        (15)        (14)        (28)
    Proceeds on sale of
     property, plant
     and equipment                     -           2           3           3
    Proceeds on sale of
     short-term investments            -           -           -         101
    Proceeds on sale of
     long-term investment              -           4           -           7
    Decrease (increase)
     in restricted cash                -          (2)          8          (3)
    Other                              -          (2)          -          (2)
    -------------------------------------------------------------------------
    Cash (used in) provided
     by investing activities          (7)        (13)         (3)         78
    -------------------------------------------------------------------------
    Financing activities
    Repayment of long-term debt       (1)         (1)         (7)        (81)
    Issuance of shares                 -           4           -           5
    Repurchase of shares               -         (12)          -         (17)
    -------------------------------------------------------------------------
    Cash used in financing
     activities                       (1)         (9)         (7)        (93)
    -------------------------------------------------------------------------

    Effect of foreign exchange
     rate changes on cash and
     cash equivalents                  5           3           1          (2)
    -------------------------------------------------------------------------
    Net increase (decrease) in
     cash and cash equivalents
     during the period                94          (5)        126         (97)
    Cash and cash equivalents,
     beginning of period             149         130         117         222
    -------------------------------------------------------------------------
    Cash and cash equivalents,
     end of period              $    243    $    125    $    243    $    125
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    MDS Inc.
    Consolidated operating highlights and reconciliation of consolidated
    adjusted EBITDA

    (millions of U.S. dollars)

    Second Quarter                                              Year-to-date
    --------------                                            ---------------
     2009    2008                                               2009    2008
    -------------------------------------------------------------------------
    $ 282   $ 350   Total revenues                             $ 557   $ 672
      (25)    (24)  Reimbursement revenues                       (43)    (50)
    -------------------------------------------------------------------------
    $ 257   $ 326   Net revenues                               $ 514   $ 622
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    $ (17)  $  13   Net (loss) income                          $ (15)  $  32
        8       6   Income tax expense                             7       -
        2      (1)  Interest expense (income), net                 4      (4)
        -       -   Change in fair value of interest rate swaps    -      (2)
       23      23   Depreciation and amortization                 45      50
    -------------------------------------------------------------------------
       16      41   EBITDA                                        41      76
        -       1   Restructuring charges, net                     6       1
       16       -   Impairment of property,                       16       -
                    plant and equipment, net
        -       3   Write-down of investments                      1       3
                    and valuation provisions
        -     (10)  Change in FDA estimate                         -     (10)
        -       -   Loss on sale of business                       -       2
       (1)     (1)  Acquisition integration                       (1)      2
    -------------------------------------------------------------------------
    $  31   $  34   Adjusted EBITDA                            $  63   $  74
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
      12%     10%   Adjusted EBITDA margin                       12%     12%
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    Consolidated operating highlights and reconciliation of consolidated
    adjusted Earnings Per Share

                               Second Quarter           Year-to-date
    -------------------------------------------------------------------------
                                    2009        2008        2009        2008
    -------------------------------------------------------------------------
    Basic (loss) earnings per
     share from operations -
     as reported                $  (0.15)   $   0.11    $  (0.13)   $   0.27
    Adjusted for:
      Restructuring charges, net       -        0.01        0.03        0.01
      Write-down of investments
       and valuation provisions        -        0.03        0.01        0.03
      Impairment of property,
       plant and equipment, net     0.11           -        0.11           -
      Change in FDA estimate           -       (0.06)          -       (0.06)
      Change in fair value
       of interest rate swaps          -           -           -       (0.02)
      Acquisition integration      (0.01)      (0.01)      (0.01)       0.01
      Write-off of tax assets       0.08           -        0.08           -
      Tax rate changes                 -           -           -       (0.09)
    -------------------------------------------------------------------------
    Adjusted earnings per
     share from operations      $   0.03    $   0.08    $   0.09    $   0.15
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    Consolidated operating highlights and reconciliation of consolidated
    adjusted Income from Continuing Operations

    (millions of U.S. dollars)
                               Second Quarter           Year-to-date
    -------------------------------------------------------------------------
                                    2009        2008        2009        2008
    -------------------------------------------------------------------------
    (Loss) income from
     operations - as reported   $    (17)   $     13    $    (15)   $     32
    Adjusted for (after tax):
      Restructuring charges, net       -           1           4           1
      Write-down of investments
       and valuation provisions        -           3           1           3
      Impairment of property,
       plant and equipment, net       13           -          13           -
      Change in FDA estimate           -          (7)          -          (7)
      Change in fair value of
       interest rate swaps             -           -           -          (2)
      Acquisition integration         (1)         (1)         (1)          1
      Write-off of tax assets          9           -           9           -
      Tax rate changes                 -           -           -         (11)
    -------------------------------------------------------------------------
    Adjusted income
     from operations            $      4    $      9    $     11    $     17
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    





For further information:

For further information: MEDIA: Janet Ko, (905) 267-4226,
janet.ko@mdsinc.com; INVESTORS: Kim Lee, (905) 267-4230, kim.lee@mdsinc.com

Organization Profile

Nordion Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890